The clinical application of anti HER2 targeted drugs represented by trastuzumab in neoadjuvant therapy, adjuvant therapy and advanced rescue therapy has changed the diagnosis and treatment mode of breast cancer, and also greatly improved the prognosis of HER2 positive breast cancer patients (18–20). This evidence concerns the gene ERBB2 and breast carcinoma.